| Global Generics | Generic pharmaceuticals across various therapeutic areas sold in regulated markets. | Robust R&D, regulatory expertise, early FDA filings, and strong US market presence. | B2B and B2C including hospitals, pharmacies, and healthcare providers globally. | Complex generics and biosimilar products with patent expiry driven opportunities. | 28981 | 89 | Sales of generic drugs through established channels in multiple countries. | Primarily direct sales with competitive pricing based on market standards. | New product launches, filings, and market expansion in North America and Europe. | Lenalidomide Capsules, Sorafenib tablets, Semaglutide injection |
| Pharmaceutical Services & Active Ingredients (PSAI) | Contract development and manufacturing services and active pharmaceutical ingredients. | Strong technology platforms, regulatory approvals, and strategic partnerships in drug development. | B2B relationships with global pharma and biotech firms. | Custom API synthesis and biologics CDMO services. | 3448 | 11 | Contract manufacturing, licensing, and supply agreements with pharmaceutical companies. | Contract-based, recurring supply agreements and project fees. | Increasing outsourcing by global pharma, specialized CDMO capabilities, and expanded API portfolio. | Aurigene Pharmaceutical Services |
| Others | Over-the-counter healthcare products and niche therapeutic offerings. | Well-known consumer brands and strategic consumer reach. | B2C general population. | Branded OTC products and niche therapies. | 215 | 0 | Sales through retail pharmacy and direct consumer channels. | Retail pricing, distribution agreements. | Consumer health demand and brand expansion initiatives. | Consumer Healthcare brands acquired from Ducere Pharma and others |
